The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.
Van Den Berg, DJ
Cancer Epidemiol Biomarkers Prev
MetadataShow full item record
Amos, C., Dennis, J., Wang, Z., Byun, J., Schumacher, F., Gayther, S., Casey, G., et al. (2017). The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.. Cancer Epidemiol Biomarkers Prev, 26 (1), 126-135. https://doi.org/10.1158/1055-9965.EPI-16-0106
BACKGROUND: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. METHODS: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. RESULTS: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. CONCLUSIONS: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. IMPACT: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126-35. ©2016 AACR.
Cancer Research UK (10124)
Cancer Research UK (10119)
Cancer Research UK (16561)
Cancer Research UK (A11020)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (656144)
National Cancer Institute (NCI) (U19CA148537)
National Cancer Institute (NCI) (U19CA148065)
External DOI: https://doi.org/10.1158/1055-9965.EPI-16-0106
This record's URL: https://www.repository.cam.ac.uk/handle/1810/260972